Huason Pharmaceutical: Abnormal fluctuations in stock trading; there are no significant matters that should be disclosed but have not been disclosed.

Huason Pharmaceutical announced that the closing price of the company's stock had deviated by more than 20% over three consecutive trading days on August 13, August 14, and August 17, 2026, indicating an abnormal fluctuation in stock trading. Upon verification, the company and its controlling shareholders, as well as actual controllers, do not have any significant matters that should be disclosed but have not been disclosed, and the controlling shareholders and actual controllers did not buy or sell the company's stock during the period of abnormal stock fluctuation. As of the close on August 17, 2026, the company's rolling price-to-earnings ratio was 53.46 times and the price-to-book ratio was 4.07 times, higher than the rolling price-to-earnings ratio of 28.89 times and price-to-book ratio of 2.68 times in the pharmaceutical manufacturing industry during the same period. The companys current production and operation situation is stable, with no significant changes, and ongoing research projects are making progress. The semi-annual report for 2026 will be disclosed on August 21, 2026.